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Type 2 diabetes (T2D) and the metabolic syndrome (MetS), two conditions that are rapidly increasing 
in prevalence, as well as the dyslipoproteinemia and subclinical inflammation characteristic for these 
conditions, are associated with an increased risk for developing and dying of cardiovascular disease 
(CVD). The aim of this thesis was to investigate possible atherogenic properties of very low-density 
lipoprotein (VLDL) and low-density lipoprotein (LDL) in T2D and MetS. We compared the 
susceptibility to lipolysis by secretory phospholipase A2 group V (sPLA2-V) of VLDL and LDL from 
individuals with T2D and MetS and from healthy individuals. We also characterized LDL-associated 
proteins, and compared the protein composition of LDL in T2D and MetS with LDL from healthy 
individuals. Finally, we investigated if lysozyme, one of the proteins that was increased in T2D-MetS-
LDL, was elevated in serum of individuals with T2D and MetS as well. 
Lipid-enriched VLDL and small, cholesterol-poor and triglyceride-rich LDL from T2D-MetS-
individuals were more extensively lipolyzed by sPLA2-V than control VLDL and LDL. 31 LDL-
associated proteins, important for lipoprotein metabolism, complement, coagulation, oxidation, and 
inflammation, were identified in LDL. VLDL and LDL from T2D-MetS-individuals contained more 
apolipoprotein (apo) C3 per particle, and an increased LDL-apoC3 content correlated with a lower 
cholesterol content of LDL and a smaller LDL-size. T2D-MetS-LDL also contained less apoA1 and 
more apoJ and lysozyme than did control LDL, and higher abundances of apoJ and lysozyme also 
correlated with a lower cholesterol content in LDL. Lysozyme was also found to be elevated in serum 
of T2D-MetS individuals, and lysozyme levels correlated with serum creatinine and insulin levels.  
The identified LDL-associated proteins might be of importance for the inflammation following LDL 
retention in the intima. An increased sPLA2-V-mediated lipolysis of VLDL and LDL in individuals 
with T2D and MetS may cause increased retention of LDL and lead to high local concentrations in the 
intima of proinflammatory fatty acids and lysophosphatidylcholine. This might lead to an accelerated 
atherosclerosis development in these individuals. An increased understanding of lipoprotein alterations 
in diabetes may furthermore serve as a basis for the development of new treatment strategies for 
atherosclerosis in T2D and MetS.  
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